RealLine Pathogen Diagnostic Kits
|
|
|
- Helen Harrison
- 6 years ago
- Views:
Transcription
1 RealLine Pathogen Diagnostic Kits for Real Time PCR Sexually Transmitted Infections Human Papilloma Virus Human Herpes Virus and others
2 Pathogen Diagnostic Kits Your Partner for Real Time PCR Detection BIORON Diagnostics GmbH is manufacturer and worldwide acting trader of diagnostic products. RealLine kits are based on the most advanced variants of PCR fast and sensitive technique BIORON products fulfil highest quality and health standards. Our customers value us for our individual concern and prompt support. Our QM-System has been certified by 2
3 Pathogen Diagnostic Kits RealLine Pathogen Kits Lyophilized Mastermixes Transport at room temperature (<10 days) Ready for use Simple procedure Same protocols for PCR and RT-PCR Controls included Less handling steps Less contamination risk CE-IVD Extraction of DNA/RNA Fast and easy Str-format Kits Fla-format Kits Real-time PCR Result Open System usable with various real-time cyclers Fluorescence Cycle Number 3
4 Pathogen Diagnostic Kits Sexually Transmitted Infections Single Kits Str-format Fla-format RealLine Chlamydia trachomatis VBD1998 VBD1996 RealLine Neisseria gonorrhoeae VBD4498 VBD4496 RealLine Mycoplasma hominis VBD4398 VBD4393 RealLine Mycoplasma genitalium VBD4396 VBD4394 RealLine Ureaplasma urealyticum VBD2298 VBD2296 RealLine Trichomonas vaginalis VBD2098 VBD2096 RealLine Gardnerella vaginalis VBD4598 VBD4596 RealLine Candida albicans VBD4698 VBD4696 RealLine Treponema pallidum VBD1898 VBD1896 Multiplex Kits Str-format Fla-format RealLine Chlamydia trachomatis / Neisseria gonorrhoeae VBD0457 VBD0458 RealLine Chlamydia trachomatis / Mycoplasma genitalium VBD0490 VBD0487 RealLine Chlamydia trachomatis / Ureaplasma urealyticum VBD0492 VBD0491 RealLine Mycoplasma genitalium / Mycoplasma hominis VBD0494 VBD0493 RealLine Ureaplasma urealyticum / Ureaplasma parvum VBD2294 VBD2295 RealLine Trichomonas vaginalis / Gardnerella vaginalis VBD0477 VBD0478 RealLine Trichomonas vaginalis / Neisseria gonorrhoeae VBD0496 VBD0495 RealLine Candida albicans / Gardnerella vaginalis VBD0444 VBD0445 4
5 Pathogen Diagnostic Kits Human Papilloma Virus High Carcinogenic Risk Types Str-format Fla-format RealLine HPV 16 / 18 VBD8473 VBD8474 RealLine HPV 31 / 33 VBD8471 VBD8480 RealLine HPV 35 / 45 VBD8469 VBD8477 RealLine HPV HCR Genotype VBD8479 VBD8482 RealLine HPV HCR Genotype quantitative VBD8478 The genotyping kits are detecting the Human Papilloma Types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 Low Carcinogenic Risk Types Str-format Fla-format RealLine HPV 6 / 11 VBD8475 VBD8481 Human Herpes Virus Product Str-format Fla-format RealLine HSV1/ HSV2 VBD2195 VBD2197 RealLine CMV quantitative VBD1598 VBD1596 RealLine EBV quantitative VBD2198 VBD2196 RealLine HHV-6 VBD2150 VBD2151 RealLine VZV VBD2185 VBD2187 Tick Borne Infections Product Str-format Fla-format RealLine TBEV (FSME) VBD1198 VBD1199 RealLine Borrelia burgdorferi s.l. VBD1498 VBD1499 RealLine Anaplasma / Ehrlichia VBD5398 VBD5399 and others Product Uni-format Str-format Fla-format RealLine Toxoplasma gondii VBD1798 VBD1796 RealLine Rubella VBD2598 VBD2596 RealLine Helicobacter pylori VBD3798 VBD3796 RealLine Mycobacterium tuberculosis VBD2398* VBD2399 *Including extraction 5
6 Pathogen Diagnostic Kits RealLine Pathogen Extraction Kits Product RealLine DNA Express RealLine DNA Extraction 2 RealLine DNA Extraction 3 RealLine Extraction 100 Clinical Material epithelial cell specimen, urine, sperm epithelial cell specimen, urine, liquor, biopsy material, blood serum, plasma epithelial cell specimen, urine, sperm, blood serum, plasma epithelial cell specimen, liquor, biopsy material, blood serum, plasma, whole blood, ticks, urine, sperm, stool MagicMag Rack Nucleic Acid Ref.No DNA VBC DNA VBC DNA VBC DNA and RNA VBC8896 Internal Control included in the Extraction Kits, but also available separately Accessories Product RealLine Internal Control MagicMag Rack Ref.No VBC8881 BI87000 Unique - available from BIORON only: The tubes remain inside the rack for the whole purification prcess. This is possible due to the built-in tilt mechanism. 6
7 Order Information To facilitate your order, please provide us with the following information Institution or company name Customer name, address, telephone number Billing address Shipping address Valid purchase order number Product number and required quantity Terms and conditions of BIORON Diagnostics GmbH Unless agreed otherwise the single transactions between client and BIORON are to be carried out according to International: The General Conditions of Export Germany: Allgemeine Geschäfts- und Lieferbedingungen Find our products in your country BIORON Diagnostics is represented in various countries worldwide. Please view the information regarding our distributors in your local area via If you do not find a distributor listed in your country please contact us directly in Germany. Imprint BIORON Diagnostics GmbH Rheinhorststr Ludwigshafen, Germany Phone Fax info@bioron.de Legal form: limited Liability Company Managing Director: dr. Ferdinand Holzinger General Manager / Prokurist: Barbara Hassib Commercial Register: ag Ludwigshafen HRB Registered Office: ludwigshafen Value Added Tax Identification Number: (VAT ID) de German Tax Number: 27/656/
8 BIORON Diagnostics GmbH Rheinhorststr Ludwigshafen Germany Rev. P Phone Fax
RealLine Pathogen Diagnostic Kits
RealLine Pathogen Diagnostic Kits for Real Time PCR SEXUALLY TRANSMITTED INFECTIONS HUMAN PAPILLOMA VIRUS HUMAN HERPES VIRUS New Edition 2018 AND OTHERS New Product: RealLine HPV HCR Screen see page 5
BIO-REFERENCE LABORATORIES, INC. 481 EDWARD H. ROSS DRIVE CITY, STATE, ZIP ELMWOOD PARK, NJ CHARLES T. TODD JR.
BID RESULTS AB2016-05 LABORATORY TESTING SERVICES FOR THE MERCER COUNTY CORRECTION CENTER FOR A PERIOD OF TWO (2) YEARS WITH THE OPTION TO EXTEND ONE (1) YEAR BID OPENING DATE: MARCH 3, 2016 AWARD TWO
Chairman s Letter. Our Purpose & Vision. Contents
ANNUAL REPORT 2017 Our Purpose & Vision Chairman s Letter Genetic Signatures is a molecular diagnostic (MDx) company that is championing diagnostic change in the global in vitro diagnostics (IVD) industry,
NorDiag ASA DnB NOR Markets SMB Seminar rd March 2010 CEO Mårten Wigstøl. Automated solutions for diagnostics & lifescience
NorDiag ASA DnB NOR Markets SMB Seminar 2010 23rd March 2010 CEO Mårten Wigstøl Automated solutions for diagnostics & lifescience 1 Disclaimer This presentation includes forward-looking statements regarding
Our Purpose & Vision. Contents
Annual Report 2018 Our Purpose & Vision Genetic Signatures is a molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary 3base platform technology. Our aim
A N N U A L R E P O R T E X E C U T I N G O U R S T R A T E G Y
Gen-Probe 2 0 0 4 A N N U A L R E P O R T E X E C U T I N G O U R S T R A T E G Y Gen-Probe (NASDAQ: GPRO) is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective
Our strategy for Sofia has been straightforward and simple, and has now been validated by our early success.
2012 ANNUAL REPORT In the near-term, we expect to introduce other respiratory assays and a qualitative pregnancy test, with the intent of solidifying and potentially expanding our existing served market.
2015 ANNUAL REPORT. Inspired Science. Trusted Solutions
2015 ANNUAL REPORT Inspired Science Trusted Solutions Meridian Bioscience, Inc. and Subsidiaries Selected Financial Data Income Statement Information (Amounts in thousands, except per share data) FY 2015
I N N O V A T I O N + E X E C U T I O N A n n u a l R e p o r t
I N N O V A T I O N + E X E C U T I O N 2006 Annual Report Gen-Probe Incorporated (NASDAQ: GPRO) is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic
Q2 and H Results. DIASORIN SPA August 3, 2017
Q2 and H1 2017 Results DIASORIN SPA August 3, 2017 Disclaimer These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future
FY Results conference call
FY 2014 Results conference call Disclaimer These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different
Test Name CPT Price Note ABO TYPE $ ACETAMINOPHEN $ 61.25
This list is provided to comply with Maine law, 22 MRSA 1718-B, requiring health care entities to maintain a list of prices and billing codes for services provided at least 50 times in the year previous
Fourth quarter and full-year 2017 results
Fourth quarter and full-year 2017 results February 1, 2018 Fourth quarter and full-year 2017 results 1 Forward looking and intended use statements Safe Harbor Statement: This presentation contains both
Call Outline. Forward Looking Statements. First Quarter 2007 Earnings Conference Call
Call Outline May 8, 2007, 9:30am EDT, 14:30 GMT, 15:30 CET First Quarter 2007 Earnings Conference Call Conference Call Outline: 1) 30 min Presentation Peer M. Schatz, CEO Roland Sackers, CFO Dr. Solveigh
QIAGEN and DIGENE Announce Merger. A New Market and Technology Leader in Molecular Diagnostics. June 4, 2007, 8:30am EST, 13:30 GMT, 14:30 CET
June 4, 2007, 8:30am EST, 13:30 GMT, 14:30 CET QIAGEN and DIGENE Announce Merger A New Market and Technology Leader in Molecular Diagnostics Conference Call Outline: 1. 30 min Presentation Peer M. Schatz,
2005 Annual Report. Connecting To New Markets
2005 Annual Report Connecting To New Markets Gen-Probe Incorporated (NASDAQ: GPRO) is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests
Proc Desc PRICE CPT VENIPUNCTURE $ CAP BLOOD DRAW $ BASIC METABOLIC PANEL $ GENERAL HEALTH PANEL $ 276.
Proc Desc PRICE CPT VENIPUNCTURE $ 17.00 36415 CAP BLOOD DRAW $ 17.00 36416 BASIC METABOLIC PANEL $ 60.00 80048 GENERAL HEALTH PANEL $ 276.00 80050 ELECTROLYTE PANEL $ 50.00 80051 COMPREHENSIVE METABOLIC
OVERVIEW. Highlights. Business and Products Development. H Financials. FY 2014 Company Guidance
H1 14 Results DISCLAIMER These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different business lines
For personal use only
Genetic Signatures Annual Report 2015 OUR VISION Genetic Signatures is a molecular diagnostics (MDx) company which operates in the global in vitro diagnostics (IVD) industry and is championing diagnostic
Q2 and H Results. DIASORIN SPA August 2, 2018
DIASORIN SPA August 2, 2018 Disclaimer These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different
2015 Enrollment Guide New Hampshire Employees
You can only enroll once a year, so don t miss your chance! 2015 Enrollment Guide New Hampshire Employees Enroll online at www.aa-benefits.com To enroll by phone, call 1-855-495-1190 Questions: Call 855-495-1190,
QIAGEN N.V. Annual Report 2000
QIAGEN N.V. Annual Report 2000 Contents 2 Report of the Supervisory Board 6 QIAGEN Keys to the Life Science Revolution 4 Letter from the Management Board 16 Contents Financial Data QIAGEN is the world
Second Quarter 2008 Earnings Conference Call
August 5, 2008, 9:30am EDT, 14:30 GMT, 15:30 CET Second Quarter 2008 Earnings Conference Call Conference Call Outline: 1) 30 min Presentation Peer M. Schatz, CEO Roland Sackers, CFO Dr. Solveigh Mähler,
Genera Biosystems Limited
ABN 69 098 663 837 Financial Report - Corporate directory Directors Company secretary Registered office Share register Auditor Stock exchange listing Website Corporate Governance Statement Mr Lou Panaccio
Q1 13 RESULTS. Conference Call
Q1 13 RESULTS Conference Call Highlights MAIN TOPICS Q1 13 Group s revenues growing when compared with Q1 12 (+1.3% at CER; +0.2% at current exchange rate) Strong and boosting revenues of tests ex Vit
HOLOGIC INC FORM 10-K. (Annual Report) Filed 11/20/14 for the Period Ending 09/27/14
HOLOGIC INC FORM 10-K (Annual Report) Filed 11/20/14 for the Period Ending 09/27/14 Address 250 CAMPUS DRIVE MARLBOROUGH, MA, 01752 Telephone (508) 263-2900 CIK 0000859737 Symbol HOLX SIC Code 3844 - X-Ray
Advanced Molecular Diagnostic Systems
Advanced Molecular Diagnostic Systems 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763-1287 F: +61 (0)3 9763-2817 www.generabiosystems.com Tuesday 1 May 2018 ASX Announcement GENERA
Third Quarter 2008 Earnings Conference Call
November 11, 2008, 9:30am ET, 14:30 GMT, 15:30 CET Third Quarter 2008 Earnings Conference Call Conference Call Outline: 1) 30 min Presentation Peer M. Schatz, CEO Roland Sackers, CFO Dr. Solveigh Mähler,
Lazard Capital Markets 9 th Annual Healthcare Conference
Lazard Capital Markets 9 th Annual Healthcare Conference November 14, 2012 Glenn P. Muir Executive VP and CFO 1 Forward-Looking Statements This presentation contains forward-looking information that involves
SEMI-ANNUAL FINANCIAL REPORT OF THE DIASORIN GROUP AT JUNE 30, 2016
SEMI-ANNUAL FINANCIAL REPORT OF THE DIASORIN GROUP AT JUNE 30, 2016 DiaSorin S.p.A. Via Crescentino (no building No.) - 13040 Saluggia (VC) Tax I. D. and Vercelli Company Register n. 13144290155 1 TABLE
For personal use only
Advanced Molecular Diagnostic Systems 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763-1287 F: +61 (0)3 9763-2817 www.generabiosystems.com Tuesday 31 January 2017 ASX Announcement GENERA
QIAGEN N.V. TABLE OF CONTENTS
QIAGEN N.V. TABLE OF CONTENTS Annual Report 2015 Report of the Supervisory Board Management Report Corporate Governance Report Corporate Governance Statement Responsibility Statement of the Management
G0476 INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); HUMAN PAPILLOMAVIRUS (HPV), HIGH-RISK TYPES (E.G
G0476 INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); HUMAN PAPILLOMAVIRUS (HPV), HIGH-RISK TYPES (E.G., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) FOR CERVICAL CANCER SCREENING, MUST
1 sur 6 05/02/ :27
1 sur 6 05/02/2013 10:27 News Releases Hologic Announces First Quarter Fiscal 2013 Operating Results Record Revenues and Adjusted Net Income BEDFORD, Mass., Feb. 4, 2013 /PRNewswire/ -- Hologic, Inc. (Hologic
Tender for. Supply and Installation of DNA/RNA Fragment Analyzer System
Tender for Supply and Installation of DNA/RNA Fragment Analyzer System Tender No. CNS/IISC/JTTO/Fragment Analyzer/06/2018 Centre for Neuroscience Indian Institute of Science Bangalore 560012 November 2018
BILLING 101. W. Scott Campbell, Ph.D, MBA Labpoint, LLC
BILLING 101 W. Scott Campbell, Ph.D, MBA Labpoint, LLC Laboratory Services Types of laboratory services Human Clinical Environmental Water Human Clinical Process Overview Patient Encounter Process specimen
For personal use only
GENETIC SIGNATURES LIMITED ACN 095 913 205 PROSPECTUS To raise up to $15 million by an Offer of up to 37,500,000 Shares at $0.40 each, with a minimum raising of $12 million LEAD MANAGER IMPORTANT NOTICES
General Purpose Financial Report Genera Biosystems Limited ACN June 2007
General Purpose Financial Report Genera Biosystems Limited 30 June 2007 Contents Page Directors' Report 3-14 Auditor's Independence Declaration 15 Income Statement 16 Balance Sheet 17 Statement of Changes
Innovation. Opportunity. Discovery. Bio-Rad Laboratories 2003 Annual Report
Innovation. Opportunity. Discovery. Bio-Rad Laboratories 2003 Annual Report BIO-RAD Laboratories is a global leader in providing INNOVATIVE tools and services to the life science research and clinical
ANNUAL FINANCIAL REPORT AT DECEMBER 31, 2012
ANNUAL FINANCIAL REPORT AT DECEMBER 31, 2012 Diasorin S.p.A. Via Crescentino (no building No.) - 13040 Saluggia (VC) Tax I. D. and Vercelli Company Register n. 13144290155 1 CONTENTS BOARD OF DIRECTORS,
REPORTS AND ACCOUNTS AT DECEMBER 31, 2004
REPORTS AND ACCOUNTS AT DECEMBER 31, 2004 DiaSorin S.p.A. Registered Office in Saluggia (VC) Share Capital 50,000,000 Tax Code and Vercelli Companies Register No. 013144290155 I N D E X Highlights and
Curetis Publishes Full-Year 2018 Financial Results and Updated Guidance for 2019
Curetis Publishes Full-Year 2018 Financial Results and Updated Guidance for 2019 - Launched Unyvero System and Unyvero LRT Cartridge in the U.S. - Increased revenues to EUR 1.4 million in 2018 - Raised
Genera Biosystems Limited
ABN 69 098 663 837 Financial Report - Corporate directory Directors Company secretary Registered office Share register Auditor Mr Lou Panaccio (Non-Executive Chairman) Mr Richard Hannebery (Chief Executive
ANNU UAL L REP E ORT 2016
Bio-Rad Laboratories ANNUAL REP ORT 2016 ACCELERATING SCIENTIFIC DISCOVERY AND IMPROVING HEALTHCARE Letter to our Shareholders We ended the year having accomplished many of the tasks we set out to do.
QIAGEN reports results for third quarter and first nine months of 2018
QIAGEN reports results for third quarter and first nine months of 2018 Q3 2018 results exceed targets as QIAGEN on track to achieve 2018 goals: o sales of $377.9 million +3.8% reported (+6.5% at constant
2011 Annual Report MOMENTUM. Securing Blood Safety
2011 Annual Report MOMENTUM Securing Blood Safety Dear Shareholder, At the end of 2011, the INTERCEPT platelet and plasma systems were in use at over 100 blood centers with kits sold to produce a cumulative
COVERAGE OPTIONS. Please refer to the table below for the percentage benefit amount for each Covered Condition.
Critical Illness Insurance Plan Summary Critical Illness Insurance COVERAGE OPTIONS Eligible Individual Initial Benefit Requirements Employee $10,000 or $20,000 Coverage is guaranteed provided you are
Nanogen Epoch Biosciences Merger Frequently Asked Questions
Filed by Nanogen, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Epoch Biosciences, Inc.
Roche Finance Report
09 Roche Finance Report Table of Contents Roche Group 2 Finance in brief 2 Finance 2009 in brief 3 Financial Review 4 Roche Group Consolidated Financial Statements 30 Notes to the Roche Group Consolidated
PATIENT INFORMATION FORM
PATIENT INFORMATION FORM : Dear Patient, We are currently updating our billing system. As a result, it is very important we received your current patient and insurance information. We appreciate your cooperation
Curetis Announces Intention to Launch Its Initial Public Offering and Listing on Euronext Amsterdam and Euronext Brussels
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT
Bergen County Gynecology, P.C.
PATIENT INFORMATION LAST NAME FIRST NAME MIDDLE MAIDEN NAME (IF ANY) DATE OF BIRTH SS# PLACE OF BIRTH MARITAL STATUS RACE ETHNICITY PREFERRED LANGUAGE OTHER LANGUAGES SPOKEN ADDRESS CITY ST ZIP HOME PHONE
Life Technologies Transplant Diagnostics Product List
Life Technologies Transplant Diagnostics Product List SECORE SKU Product Description Kit Size A11256 SECORE CUSTOM GSSP KIT 25 TESTS 5300025 SECORE LOC A SEQ KIT 25 TESTS 5311025D SECORE LOC B SEQ KIT
BENEFITS ENROLLMENT FOR NEW HIRES
BENEFITS ENROLLMENT FOR NEW HIRES Welcome to Source4Teachers/MissionOne! As a new hire, you are eligible to enroll in Company benefits for the 2016 plan year. How to Enroll You will have two options to
If you have questions, please call the BMT Authorization Specialist at , ext 5028 for assistance.
Date: Dear Dr. ; Thank you for choosing Children s Hospital & Research Center Oakland to perform the HLA typing for your patient. Please find enclosed an HLA Intake form, sample handling instructions,
Inno-Gene S.A. Fair value: PLN 9.60 Update Rating: n.a.
Inno-Gene S.A. Fair value: PLN 9.60 Update Rating: n.a. In 9M/16, Inno-Gene (IGN) generated sales of PLN 3.6m (+5.9% y-o-y). Due to a significantly higher share of personnel costs and D&A expenses EBIT
2015 N ARISO OMP C PLANS
2015 BENEFITS Maximum coverage per person Unlimited US$5,000,000 US$2,000,000 per Policy Year Age limit to apply 75 75 75 Waiting Period 30 days 30 days 30 days HOSPITALIZATION BENEFITS Coverage outside
PRESSURE BIOSCIENCES INC
SECURITIES & EXCHANGE COMMISSION EDGAR FILING PRESSURE BIOSCIENCES INC Form: 10-K Date Filed: 2013-05-13 Corporate Issuer CIK: 830656 Symbol: PBIO SIC Code: 3829 Fiscal Year End: 12/31 Copyright 2014,
Title of Manual: Specimen Collection Document Number: GPA.SPC.3.0
Page 1 of 5 I._PURPOSE Greensboro Pathology Associates provides clients with test requisitions. All test requisitions should be preprinted with client information. All specimens submitted must be sent
Lab Work Instructions
Lab Work Instructions Please read this form thoroughly before going to a lab for a blood draw or beginning to collect at home. Quest Diagnostics: Please visit their website: www.questdiagnostics.com to
TBG Diagnostics Limited
TBG Diagnostics Limited (formerly Progen Pharmaceuticals Limited) Annual Report TBG Diagnostics Limited (formerly Progen Pharmaceuticals Limited) TBG Diagnostics Limited Annual Report Contents 1 Chairman
Disclaimer for this translation:
Disclaimer for this translation: The official version of the Hesse GmbH Terms and Conditions of Ordering is the German version ( Bestellbedingungen der Hesse GmbH ). This document is a mere translation
For personal use only
Quarterly Cash Flow Report 18 October 2017 - Melbourne, Australia. Sienna Cancer Diagnostics Ltd ( Sienna or the Company ), (ASX:SDX), a commercial stage medical technology company focused on the development
Contents. Part II Statements 28 Statement by Executive Board and Supervisory Board on the Annual Report 29 Independent Auditor's Reports
Annual Report 2015 Contents Part I Management Report 3 Exiqon 4 Five-Year Key Figures and Ratios 5 2015 Highlights 6 Exiqon Life Sciences 10 Exiqon Diagnostics 14 Risks 16 Financial Performance in 2015
FY 2015 Results. 09 March 2016
FY 2015 Results 09 March 2016 Disclaimer These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different
Akers Biosciences, Inc. (Incorporated in the State of New Jersey, USA under the New Jersey Business Corporation Act)
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document you should consult your stockbroker, bank manager, solicitor, accountant or
CERUS CORPORATION (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
OUT-OF-NETWORK MEMBER PAYS IN-NETWORK MEMBER PAYS. Contract Year Plan Deductibles. services and prescription drugs) Out-of-Pocket Maximum
FlexPOS-CNT-HSA-6000I/12000F-01 Open Access Contract Year Benefit Summary (E) Point-Of-Service Open Access High Deductible Health Plan (HDHP) for use with a Health Savings Account (HSA) This is a brief
IN-NETWORK MEMBER PAYS OUT-OF-NETWORK MEMBER PAYS. Calendar Year Plan Deductible. services and prescription drugs) Out-of-Pocket Maximum
POS HDHP $3,000/$6,000 Deductible-F Point-of-Service Open Access High Deductible Health Plan for use with a Health Savings Account (HSA) Benefit Summary This is a brief summary of benefits. Refer to your
Curetis secures financing facility of up to EUR 20 million through the issuance of convertible notes
Curetis secures financing facility of up to EUR 20 million through the issuance of convertible notes - Funding enables further acceleration of commercial expansion and R&D programs - EUR 3.5 million of
SECURITIES AND EXCHANGE COMMISSION Washington, D.C
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended
General Terms and Conditions of Business. Lifetime Services
General Terms and Conditions of Business Lifetime Services General These General Terms and Conditions of TGW Group (hereinafter referred to as "TGW"), applicable for TGW Systems Integration GmbH, TGW Mechanics
What is critical illness insurance?
Frequently Asked Questions Critical Illness Insurance What is critical illness insurance? This is coverage that can help cover the extra expenses associated with a serious illness. When a serious illness
EX a82851a3exv99w1.htm INFORMATION STATEMENT
EX-99.1 3 a82851a3exv99w1.htm INFORMATION STATEMENT GEN-PROBE LOGO EXHIBIT 99.1 10210 Genetic Center Drive San Diego, California 92121 September 2, 2002 Dear Chugai Pharmaceutical Shareholder, It is my
BIOCARTIS ANNOUNCES INTENTION TO LAUNCH AN INITIAL PUBLIC OFFERING ON EURONEXT BRUSSELS
THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL, OR AN INVITATION TO OFFER TO BUY OR SUBSCRIBE FOR, SECURITIES. INVESTORS WILL NEED TO BASE THEIR INVESTMENT DECISION ON THE PROSPECTUS AND PARTICULARLY
AUTHORIZATION TO USE, DISCLOSE, & RELEASE PROTECTED HEALTH INFORMATION
AUTHORIZATION TO USE, DISCLOSE, & RELEASE PROTECTED HEALTH INFORMATION I understand the following: I have the right to refuse to sign this form for authorization to disclose or release my protected health
2016 Draft Operating Budget for the Ottawa Board of Health. Tabled November 9, 2015 DOCUMENT 1
Draft Operating for the Ottawa Board of Health Tabled November 9, 2015 DOCUMENT 1 Ottawa Public Health Briefing Note Description The Ottawa Board of Health through Ottawa Public Health (OPH) seeks to improve
Third consecutive profitable quarter with continued strong growth
Interim report for the period 1 January 30 September 2015 Announcement No. 10/2015 To NASDAQ Copenhagen Exiqon A/S Skelstedet 16 2950 Vedbæk Denmark 26 October 2015 Phone: +45 4566 0888 Fax: +45 4566 1888
These Sales Conditions apply to all entrepreneurs, legal entities under public law and special funds under public law.
Conditions of Delivery and Payment - Velleuer GmbH + Co. KG As of: March 2018 1. Scope These Sales Conditions apply to all entrepreneurs, legal entities under public law and special funds under public
Molecular Diagnostic Solutions for Urologic Cancer
2018 All rights reserved 1 Molecular Diagnostic Solutions for Urologic Cancer 2017 Full Year Financial Results February 22, 2018 2 Forward Looking Statement This presentation contains forward-looking statements
Welcome to Hawaii Women s Healthcare
Cheryl Lynn T. Rudy, M.D. Cheryl L. Leialoha, M.D. Erin C. Gertz, M.D. Laura A. Spector, D.O. Andrea Wieland, APRN Welcome to Hawaii Women s Healthcare Hawaii Women s Healthcare strives to provide you
Universal Biosensors announces FY2015 results showing strong revenue growth and positive operating cash flow
ARBN 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email info@universalbiosensors.com www.universalbiosensors.com 17 th February 2016
Research Report Update Investors should consider this report as only a single factor in making their investment decision.
Research Report Update Investors should consider this report as only a single factor in making their investment decision. Please view our Disclosures on pages 14 16. 790 New York Ave, Huntington, New York,
BLAKE FRIEDEN MD, PA Registration Form
BLAKE FRIEDEN MD, PA Registration Form Name: Today s Date: First Middle Last Home Address: City: State: Zip: Telephone: ( ) Birthdate: Age: Cell Phone: ( ) Social Security Number - - Race/Ethnicity: White
QUARTERLY CASH FLOW REPORT PERIOD ENDED 30 JUNE 2006
QUARTERLY CASH FLOW REPORT PERIOD ENDED 30 JUNE 2006 Attached is the Appendix 4C Quarterly Cash Flow Report for Starpharma Holdings Ltd (ASX:SPL, USOTC:SPHRY) for the quarter ended 30 June 2006. Cash on
Subscription Application Form Major Medical Expense Insurance
ajor edical Expense Insurance Page 1 of 5 New policy Addition of dependent Plans Deductible Rehabilitation Change of plan Optimum Plus Option I $1,000 Inclusion Other Optimum Option II $2,000 requency
SEMI-ANNUAL FINANCIAL REPORT JUNE 30, 2017
SEMI-ANNUAL FINANCIAL REPORT JUNE 30, 2017 DiaSorin S.p.A. Via Crescentino (no building No.) - 13040 Saluggia (VC) Tax I. D. and Vercelli Company Register n. 13144290155 1 TABLE OF CONTENTS REPORT ON OPERATIONS...
Reverse Transcription Reagent
ExoComplete Reverse Transcription Reagent For cdna synthesis on mrna Capture Plate or mrna Capture 8-well Strip For use in real-time two-step qrt-pcr INSTRUCTION MANUAL For Research Use Only 630 Clyde
An ACA Health Plan Solution for Employers and their Employees
An ACA Health Plan Solution for Employers and their Employees Qualified Health Plans QHP 1M healthcare professionals 42+ serving the National Coverage Aliera Healthcare is a new and innovative healthcare
Meridian Diagnostics, Inc. dba. Bioscience, Inc ANNUAL REPORT. Better Medicine. Through. Better Science
Meridian Diagnostics, Inc. dba Bioscience, Inc. 2000 ANNUAL REPORT Better Medicine Through Better Science SELECTED FINANCIAL DATA Meridian Diagnostics, Inc. dba Meridian Bioscience, Inc. and Subsidiaries
Member Center Terms & Conditions
Member Center Terms & Conditions Revised 4/2/18 I. GENERAL 1. The Member Center ( MC ) wishes to enroll participants into the National Kidney Registry ( NKR ) program so the NKR can to facilitate kidney
Starmark Preventive PlusSM
Compliant with the Affordable Care Act as it applies to self-funded plans Starmark Preventive PlusSM Minimum Essential Coverage Plan Designs Self-Funded Health Plan Designs and Stop-Loss Insurance for
Critical Illness Insurance
Critical Illness Insurance Sponsored by Administered by ADF# CI1912.18 Important benefits for CSEA retirees Many individuals have had a family member, friend or acquaintance who has felt the physical,
APPLERA CORPORATION ANNUAL REPORT
ANNUAL REPORT 2006 A p p l i e d B i o s y s t e m s C e l e r a G e n o m i c s applera corporation consists of the following businesses: has two classes of common stock. Applera Corporation Applied Biosystems
of TGW Software Services GmbH for Lifetime Services 07/2014
of TGW Software Services GmbH for Lifetime Services 07/2014 General These General Terms and Conditions of TGW Software Services GmbH (hereinafter referred to as "TGW") form an integral part of the business
HOSPITAL PRICING MOST COMMON ITEMS AS OF 06/18/18
EMERGENCY DEPARTMENT VISITS (NURSING) 99281 ER LEVEL 1 $ 77.00 99282 ER LEVEL 2 $ 196.00 99283 ER LEVEL 3 $ 298.00 99284 ER LEVEL 4 $ 486.00 99285 ER LEVEL 5 $ 833.00 99291 ER LEVEL 6 (CRITICAL CARE) $
Minimum Essential Coverage (MEC) and Minimum Value Plan (MVP)
BENEFIT PLAN PROPOSAL Minimum Essential Coverage (MEC) and Minimum Value Plan (MVP) Prepared for: Sample Prepared by: Jessica Griffiths Date: Proposal number: Policy Term: Managed Care Administrators Managed
Vermont Department of Health
Vermont Department of Health Sealed Bid Request for Proposals Project Title: Tick and Tickborne Disease Surveillance Contract Period: 3/1/2013 2/28/2014 Date RFP Issued: 11/16/2012 Date of Bid Closing:
DEMOGRAPHICS Patient Name *Orientation: *Race. Please Print. *Required Fields
*First Heterosexual Decline to Answer Middle Homesexual American Native *Last Bisexual Asian Suffix Other Black Previous First Don't Know Hispanic Previous Last Decline to Answer Pacific Islander *Date
DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS DIRECTOR'S OFFICE GENERAL INDUSTRY SAFETY AND OCCUPATIONAL HEALTH STANDARD STANDARDS
DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS DIRECTOR'S OFFICE GENERAL INDUSTRY SAFETY AND OCCUPATIONAL HEALTH STANDARD STANDARDS Filed with the secretary of state on These rules take effect immediately